| 360 | 0 | 1 |
| Downloads | Citas | Reads |
The aimed to systematically evaluate the in vivo ameliorative effects of Ganoderma lingzhi mycelium polysaccharides (GL) on type 2 diabetes mellitus (T2DM) and to elucidate the underlying mechanisms involving intestinal barrier function and gut microbiota regulation. The results demonstrated that GL intervention dose-dependently alleviated the symptoms of polydipsia， polyphagia， and body weight loss in T2DM mice， and significantly reduced fasting blood glucose levels. In terms of metabolic regulation， GL effectively decreased the levels of TC， TG， LDL-C， and FFA in both serum and liver， while increasing the HDL-C levels. GL also improved liver function， as indicated by reduced serum activities of ALT and AST， and enhanced the body's antioxidant capacity， manifested by significantly increased activities of SOD and CAT， along with a decrease in MDA content. HE analysis further confirmed that GL mitigated hepatic steatosis and damage to colonic mucosal structure. Mechanistic investigations revealed that GL intervention significantly up-regulated the protein and gene expression of intestinal tight junction proteins (ZO-1， Claudin-1， Occludin)， lowered serum levels of pro-inflammatory cytokines including TNF-α， IL-1β， and IL-6 levels， and promoted the gene expression of mucin MUC2. 16S rRNA sequencing analysis indicated that GL remodeled the disordered gut microbiota structure by increasing microbial alpha diversity. GL adjusted the Firmicutes/Bacteroidota ratio at the phylum level， and significantly elevating the relative abundance of beneficial genera such as Akkermansia， Lactobacillus， and Blautia at the genus level. In conclusion， GL exert their ameliorative effects on T2DM through multi-target synergistic actions， which include regulating glucose and lipid metabolism， improving oxidative stress and liver injury， effectively maintaining intestinal barrier integrity， suppressing systemic inflammation， and modulating gut microbiota homeostasis. This study provides new mechanistic evidence supporting the potential application of GL as a functional food or adjuvant therapy for T2DM.
[1] 张雨辰，张雅琴. 糖尿病类型及并发症的研究进展[J]. 基因组学与应用生物学. 2021， 40(02): 958-960.
[2] 闫聪，王琪格，战丽彬. 肠黏膜屏障在2型糖尿病中的作用机制及中医药干预研究进展[J]. 四川大学学报(医学版). 2025， 56(03): 619-626.
[3] Sevgican D， P N P， Stephan H， et al. Emerging Targets in Type 2 Diabetes and Diabetic Complications.[J]. Advanced science (Weinheim， Baden-Wurttemberg， Germany). 2021， 8(18): e2100275.
[4] 孙顺，郑玉玲，钟达源，等. 葛根芩连汤治疗T2DM研究进展[J]. 中华中医药学刊.: 1-9.
[5] 侯倩宜. 多酚化合物LM49对Ⅱ型糖尿病大鼠肠黏膜屏障的保护作用及机制研究[D]. 山西中医药大学， 2022.
[6] 李宝铜，钟斯然，朱盼，等. 中药调控肠道菌群影响2型糖尿病的研究进展[J]. 壮瑶药研究. 2025(01): 151-154.
[7] Jinjie L， Ge Y， Qihe Z， et al. Function of Akkermansia muciniphila in type 2 diabetes and related diseases.[J]. Frontiers in microbiology. 2023， 14: 1172400.
[8] Key Laboratory Of Dairy Science M O E N， Key Laboratory Of Dairy Science M O E N， Key Laboratory Of Dairy Science M O E N， et al. Lactobacillus acidophilus alleviates type 2 diabetes by regulating hepatic glucose， lipid metabolism and gut microbiota in mice.[J]. Food & function. 2019， 10(9): 5804-5815.
[9] 王侗逊，刘蓝天，李润琪，等. 基于TLR4/NF-κB/NLRP3信号通路介导的炎症探究降糖3号方改善DM大鼠脂肪组织胰岛素抵抗的机制[J]. 中国实验方剂学杂志.: 1-12.
[10] Xiaoxia C， Junlin W， Xiong F， et al. Fructus mori polysaccharide alleviates diabetic symptoms by regulating intestinal microbiota and intestinal barrier against TLR4/NF-κB pathway.[J]. International journal of biological macromolecules. 2023， 249: 126038.
[11] Yang L， Hou H， Yan H， et al. Molecular mechanism and structure-activity relationships of natural source polysaccharides in intervening type 2 diabetes mellitus through antioxidant effects: A systematic review[J]. Carbohydrate Polymers. 2026， 377: 124830.
[12] 罗虹建，鲁国东，林占熺，等. 灵芝主要活性成分药理作用及生物合成研究进展[J]. 中草药. 2025， 56(09): 3366-3379.
[13] 薛建邦，肖裕玲，田怡，等. 灵芝航天诱变菌株的鉴定与筛选[J]. 食品科技. 2025， 50(05): 1-9.
[14] Nie B， Chen J， Wang W， et al. Structural and functional benefits of Ganoderma lingzhi polysaccharides due to space mutagenesis[J]. Carbohydrate Polymers. 2025， 358: 123532.
[15] 董力冉，王天赐，贾滋坤，等. 航天育种灵芝菌丝体多糖的体外降糖降脂活性[J]. 菌物研究. 2025， 23(01): 54-60.
[16] Kim H， Nelson P， Nzabarushimana E， et al. Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease[J]. Nature Metabolism. 2025， 7(7): 1-17.
[17] Ling S， Chuanxin X， Jintao Y， et al. A polysaccharide from Inonotus obliquus ameliorates intestinal barrier dysfunction in mice with type 2 diabetes mellitus.[J]. International journal of biological macromolecules. 2022， 214: 312-323.
[18] Carvalho F A， Koren O， Goodrich J K， et al. Transient Inability to Manage Proteobacteria Promotes Chronic Gut Inflammation in TLR5-Deficient Mice[J]. Cell Host & Microbe. 2012， 12(2): 139-152.
[19] Zheng T， Hao H， Liu Q， et al. Effect of Extracelluar Vesicles Derived fromAkkermansia muciniphilaon Intestinal Barrier in Colitis Mice[J]. Nutrients. 2023， 15(22).
[20] Bingyong M， Weiling G， Xuemei L， et al. Potential Probiotic Properties of Blautia producta Against Lipopolysaccharide-Induced Acute Liver Injury.[J]. Probiotics and antimicrobial proteins. 2023， 15(3): 785-796.
[21] 尚书菊，徐昕，谢义，等. 灵芝多糖调节AMPK/PGC-1α信号通路改善运动性疲劳小鼠腓肠肌糖脂代谢紊乱[J]. 食品科学. 2025， 46(23): 206-214.
[22] 韦博艺，李冰，赵浩如，等. 嗜黏蛋白阿克曼菌改善肠道屏障损伤的作用机制研究[J]. 食品工业科技.: 1-21.
[23] 董新燕，刘雪，刘曼妮，等. 嗜粘蛋白阿克曼菌在糖尿病和肥胖中的作用[J]. 微生物学报. 2020， 60(05): 856-863.
[24] Dicks L M T. How important are fatty acids in human health and can they be used in treating diseases?[J]. Gut microbes. 2024， 16(1): 2420765.
[25] Malai T， Chandra I， K S J， et al. Lactobacillus saerimneri and Lactobacillus ruminis: novel human‐derived probiotic strains with immunomodulatory activities[J]. FEMS microbiology letters. 2009， 293(1): 65-72.
[26] Dong Y， Zhang L， Di Qiu， et al. Lactobacillus murinus ZNL-13 Modulates Intestinal Barrier Damage and Gut Microbiota in Cyclophosphamide-Induced Immunosuppressed Mice.[J]. Foods (Basel， Switzerland). 2025， 14(8): 1416.
[27] Yonghao F， Aiqun C， Qiong L， et al. The Protective Effect of Astaxanthin on Cognitive Function via Inhibition of Oxidative Stress and Inflammation in the Brains of Chronic T2DM Rats.[J]. Frontiers in pharmacology. 2018， 9: 748.
Basic Information:
DOI：10.13341/j.jfr.2026.1982
China Classification Code:TS201.4;R285.5
Citation Information:
[1]LI Jing,DONG Liran,SU Ling ,et al.Study on the Improvement of Type 2 Diabetes by Ganoderma lingzhi Mycelium Polysaccharides Based on Intestinal Barrier and Gut Microbiota Regulation[J].Journal of Fungal Research().DOI:10.13341/j.jfr.2026.1982.
Fund Information:
北方重要食药用菌种质资源开发与利用联合研究中心建设项目
2026-04-07
2026-04-07
2026-04-07